| Literature DB >> 35978691 |
Andrew D Huber1, Yongtao Li1, Wenwei Lin1, Annalise N Galbraith1, Ashutosh Mishra2, Shaina N Porter3,4, Jing Wu1, Rebecca R Florke Gee1,5, Wei Zhuang1, Shondra M Pruett-Miller3,4, Junmin Peng2,6,7, Taosheng Chen1.
Abstract
We previously reported a specific inverse agonist (SPA70) of the nuclear receptor pregnane X receptor (PXR). However, derivatization of SPA70 yielded only agonists and neutral antagonists, suggesting that inverse agonism of PXR is difficult to achieve. Therefore, we sought to design proteolysis targeting chimeras (PROTACs) aimed at inducing PXR degradation. Conjugation of a SPA70 derivative to ligands of the E3 substrate receptor cereblon (CRBN) resulted in one molecule, SJPYT-195, that reduced PXR protein level in an optimized degradation assay described here. Further analysis revealed that SJPYT-195 was a molecular glue degrader of the translation termination factor GSPT1 and that GSPT1 degradation resulted in subsequent reduction of PXR protein. GSPT1 has recently gained interest as an anticancer target, and our results give new insights into chemical determinants of drug-induced GSPT1 degradation. Additionally, we have developed assays and cell models for PXR degrader discovery that can be applied to additional protein targets.Entities:
Year: 2022 PMID: 35978691 PMCID: PMC9377019 DOI: 10.1021/acsmedchemlett.2c00223
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.632